(137 days)
Not Found
Not Found
No
The description details a reflectance photometer and microprocessor calculating results based on stored calibration parameters, which is standard digital signal processing, not AI/ML. There is no mention of AI, ML, or related concepts like training or inference.
No
The device measures hCG levels to aid in the assessment of pregnancy status, which is a diagnostic function, not a therapeutic one. It does not treat or prevent any condition.
Yes
Explanation: The device is used for the quantitative measurement of human chorionic gonadotropin (hCG) in whole blood samples, and is explicitly stated as "an aid in the assessment of pregnancy status," which is a diagnostic purpose.
No
The device description clearly outlines numerous hardware components including optics, a printed circuit board, batteries, photodetectors, LEDs, reagent strips, a chemistry pad, and an LCD. This is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative measurement of human chorionic gonadotropin (total ßhCG) in capillary and venous whole blood samples" and is used "as an aid in the assessment of pregnancy status." This involves testing a sample taken from the human body to provide information about a physiological state.
- Device Description: The description details a device that uses "dry reagent chemistry strips" and "lateral flow immunoassays" to measure a substance (hCG) in a biological sample (whole blood). This is a common characteristic of IVD devices.
- Sample Type: The device analyzes "capillary and venous whole blood samples," which are biological specimens.
- Measurement: It performs a "quantitative measurement" of hCG, providing a numerical result.
- Professional Use: While it's for professional use, this doesn't preclude it from being an IVD. Many IVDs are used by healthcare professionals.
The definition of an In Vitro Diagnostic device generally includes reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. This device fits this description by measuring a marker (hCG) in a biological sample to aid in assessing pregnancy status.
N/A
Intended Use / Indications for Use
DRx® Qt. hCG is a rapid, single-use, point-of-care device for the quantitative measurement of human chorionic gonadotropin (total ßhCG) in capillary and venous whole blood samples. The device is for professional use as an aid in the assessment of pregnancy status.
The DRx® Qt. hCG Control Set is a two level, assayed, liquid control containing human chorionic gonadotropin for the evaluation of precision and accuracy of the DRx Qt. hCG device.
Product codes (comma separated list FDA assigned to the subject device)
DHA, JJX
Device Description
The DRx® Ot. hCG device is a single-use, disposable four-channel reflectance photometer integrated with dry reagent chemistry strips and contained within a sealed plastic case. Each unit consists of:
. an optics subassembly that also supports the reagent strips
- a printed circuit board that includes a microprocessor, analog . electronics, battery clips, batteries, silicon diode photodetectors, and j light emitting diodes (LEDs)
- a plastic molded part ("spider") that supports the liquid crystal display ● (LCD), the sample pad and the auto start leads, and also provides optical shielding
- two reagent strips .
- whole blood separation chemistry pad ●
- a desiccant
- liquid crystal display (LCD)
Both test strips are lateral flow immunoassays for measuring hCG between zero and 10,000 mIU/mL. In both strips, a blue color is measured in discrete test zones. The test zones are the areas where the specific reactions occur and concentrations are measured.
The whole blood separation mechanism occurs when the whole blood ~ sample reaches the sample pad and immobilizes the red blood cells. As a result, the plasma freely migrates by capillary action onto the assay strips to complete the final reactions. The hCG reaction proceeds as follows: anti-hCG antibody, conjugated to blue microparticles, migrate across the strip upon the addition of whole blood sample. The amount of blue microparticles captured on the test zones is proportional to the amount of hCG in the sample.
The LEDs and silicon photodetectors compare the reflectances of the color intensities before and after the sample addition. Based on the calibration parameters stored in memory, the numerical concentrations of hCG is calculated. The final assay results are expressed in mIU/mL hCG.
The DRx® Qt. hCG Control Set is a bovine plasma-based, liquid, 2-level control set to be used in quality control procedures with the DRx® Qt. hCG test. The assayed control set is used for evaluating precision and systematic analytical deviations that may arise from device variations.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical Data (Device): Studies were conducted that evaluated hCG for analytical sensitivity, analytical specificity, and linearity.
- Sensitivity: The device is sensitive to 5 mIU/mL hCG.
- Specificity: DRx® Qt. hCG results were not affected by the addition of potential interferents (biological compounds and therapeutic agents) or potential cross-reactants (hLH, hFSH, and hTSH). The device is specific for total beta hCG subunit present as intact hCG or free beta subunit.
- Linearity: Dynamic ranges of 5 to 10,000 mIU/mL for hCG were confirmed.
Clinical Data (Device): Accuracy was evaluated by comparative testing between DRx Qt. hCG and Stratus® BhCG as the predicate method.
- Accuracy (Venous): 96 venous whole blood samples were assayed by DRx® Qt. hCG (across four "POL" clinical sites and in-house) and by the predicate method.
- Linear Regression Equation: y = 0.92x + 20
- Correlation Coefficient: 0.98
- Accuracy (Fingerstick): 63 matched whole blood capillary (fingerstick) samples were collected at clinical sites and compared to venous samples tested in DRx® Qt. hCG assay to demonstrate equivalence of sample.
- Linear Regression Equation: y = 1.05x + 8
- Correlation Coefficient: 0.96
- Equivalence (DRx® venous vs. DRx® fingerstick):
- Linear Regression Equation: y = 1.06x - 6
- Correlation Coefficient: 0.99
- Precision: Evaluated at three sites by repeat testing of a 3-level whole blood precision panel (low, middle, and high hCG levels) on a single day.
- Coefficients of variation ranged from 8.3% to 15.1% across the three sites.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
- Sensitivity: 5 mIU/mL hCG.
- Specificity: Not affected by potential interferents or cross-reactants; specific for total beta hCG subunit.
- Precision: Coefficients of variation ranged from 8.3% to 15.1%.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Stratus® ßhCG (Dade Behring Inc., Miami, FL)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
M = T R I K A
Metrika, Inc. 510 Oakmead Parkway Sunnyvale, CA 94086 main 408 524 2255 fax 408 524 2252
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is K991532.
| 807.92 (a)(1): Name: | Metrika, Inc. |
|---|---|
| Address: | 510 Oakmead Parkway |
| Sunnyvale, CA 94086 | |
| Phone: | (408) 524-2255 |
| FAX: | (408) 524-2252 |
| Contact: | Stephen J. Hardt |
807.92 (a)(2): Device name- trade name and common name, and classification
| Trade name (Device): | DRx® Qt. hCG |
|---|---|
| Common Name (Device): | whole blood hCG immunoassay system |
| Classification (Device): | 21 CFR 862.1155 |
| Trade name (Control): | DRx® Qt. hCG Control Set |
|---|---|
| Common Name (Control): | assayed hCG control |
Classification (Control): 21 CFR 862.1660
807.92 (a)(3): Identification of the legally marketed predicate device
(Device)
DRx® Qt. hCG is substantially equivalent to the commercially available predicate device, Stratus® ßhCG (Dade Behring Inc., Miami, FL). DRx Ot. hCG reports a single result without additional off-line dilutions or whole blood specimen manipulations. Stratus® requires dilutions of samples greater than 1000 mIU/mL and sample centrifugation (for plasma) prior to evaluations in order to report the final result.
(Control)
Dade® Immunoassay Controls Comprehensive Tri-Level Name: Manufacturer: Dade International, Inc.
1
807.92 (a)(4): Device Description
(Device)
The DRx® Ot. hCG device is a single-use, disposable four-channel reflectance photometer integrated with dry reagent chemistry strips and contained within a sealed plastic case. Each unit consists of:
. an optics subassembly that also supports the reagent strips
- a printed circuit board that includes a microprocessor, analog . electronics, battery clips, batteries, silicon diode photodetectors, and j light emitting diodes (LEDs)
- a plastic molded part ("spider") that supports the liquid crystal display ● (LCD), the sample pad and the auto start leads, and also provides optical shielding
- two reagent strips .
- whole blood separation chemistry pad ●
- a desiccant
- liquid crystal display (LCD)
Both test strips are lateral flow immunoassays for measuring hCG between zero and 10,000 mIU/mL. In both strips, a blue color is measured in discrete test zones. The test zones are the areas where the specific reactions occur and concentrations are measured.
The whole blood separation mechanism occurs when the whole blood ~ sample reaches the sample pad and immobilizes the red blood cells. As a result, the plasma freely migrates by capillary action onto the assay strips to complete the final reactions. The hCG reaction proceeds as follows: anti-hCG antibody, conjugated to blue microparticles, migrate across the strip upon the addition of whole blood sample. The amount of blue microparticles captured on the test zones is proportional to the amount of hCG in the sample.
The LEDs and silicon photodetectors compare the reflectances of the color intensities before and after the sample addition. Based on the calibration parameters stored in memory, the numerical concentrations of hCG is calculated. The final assay results are expressed in mIU/mL hCG.
(Control)
The DRx® Qt. hCG Control Set is a bovine plasma-based, liquid, 2-level control set to be used in quality control procedures with the DRx® Qt. hCG test. The assayed control set is used for evaluating precision and systematic analytical deviations that may arise from device variations.
2
807.92 (a)(5): Intended use
(Device)
The DRx® Ot. hCG is a rapid, single-use, point-of-care device for the quantitative measurement of human chorionic gonadotropin (total ßhCG) in capillary and venous whole blood. The device is for professional use as an aid in the assessment of pregnancy status.
(Control)
The DRx® Qt. hCG Control Set is a two level, assayed, liquid control containing human chorionic gonadotropin for the evaluation of precision and accuracy of the DRx® Qt. hCG device.
807.92 (a)(6): Technological Similarities and Differences to the Predicate
| CHARACTERISTIC | DRx® Qt. hCG | Stratus® βhCG
K850570 |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | DRx® Qt. hCG is a rapid, single-
use, point-of-care device for the
quantitative measurement of
human chorionic gonadotropin
(total βhCG) in capillary and
venous whole blood samples.
The device is for professional use
as an aid in the assessment of
pregnancy status. | The Stratus βhCG Fluorometric
Enzyme Immunoassay is for
quantitative determination of
total beta human chorionic
gonadotropin (βhCG) levels in
serum and plasma for the
detection of pregnancy. |
| Analyte(s) | hCG (mIU/mL)
WHO 3rd IS 75/537 | hCG (mIU/mL)
WHO 3rd IS 75/537 |
| Testing Matrix
(Specimen Type) | Plasma
(after integrated red blood cell
separation) | Serum and plasma |
| Testing Environment | professional use | professional use |
| Risk to Patient | not a sole discriminant; hCG
results are interpreted along with
medical histories and other
diagnostic procedures. | not a sole discriminant; hCG
results are interpreted along with
medical histories and other
diagnostic procedures. |
Similarities Between DRx® Ot. hCG and Stratus® BhCG
3
807.92 (a)(6): Technological Similarities and Differences to the Predicate (continued)
| CHARACTERISTIC | DRx® Qt. hCG | Stratus® βhCG K850570 |
|---|---|---|
| Methodology/Testing | ||
| Platforms | DRx® Qt. hCG is a four channel, reflectance photometer (plus an internal reference channel) with integral dry chemistry strips. | Stratus® βhCG is a Fluorometric Enzyme Immunoassay. |
| Reportable Ranges | 5 to 10,000 mIU/mL | 2 to 1000 mIU/mL |
| Dilutions | Not required | Required for samples greater than 1000mIU/mL hCG |
| Specimen Processing | Not required | |
| (straight addition of whole blood specimen into device for testing) | Required | |
| (centrifugation of whole blood specimen to obtain serum or plasma before testing) |
Differences Between DRx® Qt. hCG and Stratus® ßhCG
:
4
807.92 (a)(6): Technological Similarities and Differences to the Predicate (continued)
| and Dade® Immunoassay Controls Comprehensive Tri-Level | ||
|---|---|---|
| CHARACTERISTIC | DRx® Qt. hCG Control Set | Dade® Immunoassay |
| Controls Comprehensive | ||
| Tri-Level | ||
| K860906 | ||
| Intended Use | The DRx® Qt. hCG Control Set is | |
| a two level, assayed, liquid control | ||
| containing human chorionic | ||
| gonadotropin for the evaluation of | ||
| precision and accuracy of the | ||
| DRx® Qt. hCG device. | Dade® Immunoassay Controls | |
| Comprehensive Tri-Level are | ||
| intended to assist in | ||
| monitoring accuracy and | ||
| precision in clinical assays. | ||
| Testing Environment | professional use | professional use |
| Test Method | quantitative | quantitative |
Similarities Between DRx® Qt. hCG Control Set d Dade® Immunoassay Controls Comprehensive Tri-Level
Differences Between DRx® Qt. hCG Control Set
and Dade® Immunoassay Controls Comprehensive Tri-Level
| CHARACTERISTIC | DRx ® Qt. hCG Control Set | Dade® Immunoassay Controls Comprehensive
Tri-Level
K860906 |
|----------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Analyte(s) | hCG | (Various constituents), e.g.
Acetaminophen Lidocaine
Digoxin TSH
Vitamin B12 hGH
FSH PSA
hCG hLH, etc. |
| Matrix | Liquid, bovine plasma-based matrix with spiked human-based analyte | Lyophilized, human source materials |
The differences in the two testing platforms for either devices or control materials do not raise new issues of safety and effectiveness.
ﮐﮯ ﻣ
5
807.92 (b)(1): Brief Description of Nonclinical Data (Device)
Studies were conducted that evaluated hCG for analytical sensitivity. analytical specificity, and linearity.
Sensitivity studies demonstrated that the device is sensitive to 5 mIU/mL hCG.
DRx® Qt. hCG results were not affected by the addition of potential interferents such as biological compounds and therapeutic agents found routinely in blood. In addition, DRx® Qt. hCG results were not affected by potential cross/reactants similar to alpha hCG homology such as hLH, hFSH, and hTSH. The device is specific for total beta hCG subunit present as intact hCG or free beta subunit.
Linearity studies confirmed dynamic ranges of 5 to 10,000 mIU/mL for hCG.
807.92 (b)(2): Brief Description of Clinical Data (Device)
Accuracy was evaluated by comparative testing between DRx Ot. hCG and Stratus® BhCG as the predicate method. Ninety-six (96) venous whole blood samples were assayed by DRx® Ot. hCG among four "POL" clinical sites and in-house, and by the predicate method. In addition, 63 matched whole blood capillary (fingerstick) samples were collected at the These fingerstick samples were compared to venous clinical sites. samples tested in DRx® Qt. hCG assay to demonstrate equivalence of sample. The data are summarized below (predicate method = X-axis).
| | n samples | Linear Regression
Equation | Correlation
Coefficient |
|--------------------------------------------|-----------|-------------------------------|----------------------------|
| hCG
(venous compared to predicate) | 96 | $y = 0.92x + 20$ | 0.98 |
| hCG
(fingerstick compared to predicate) | 63 | $y = 1.05x + 8$ | 0.96 |
| hCG
(DRx® venous vs. DRx® fingerstick) | 63 | $y = 1.06x - 6$ | 0.99 |
CLINICAL LINEAR REGRESSION DATA
Precision was evaluated at three sites by repeat testing of a 3-level whole blood precision panel (low, middle, and high hCG levels) on a single day. The coefficients of variation ranged from 8.3% to 15.1% across the three sites.
6
807.92 (b)(3): Conclusions from Nonclinical and Clinical Testing (Device)
Studies demonstrated substantial equivalence between DRx® Qt. hCG and an existing product already being marketed in terms of accuracy and precision. Sensitivity and linearity studies confirmed the assay's reportable range, and interference substance studies confirmed the assay's specificity.
7
Image /page/7/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized image of three human profiles facing to the right, resembling a bird-like shape.
SEP 1 7 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Ya-Chen Hsu Clinical Research Associate Metrika, Inc. 510 Oakmead Parkway Sunnyvale, California 94086
Re: K991532
Trade Name: DRx® Qt. hCG Regulatory Class: II Product code: DHA Regulatory Class: I reserved Product Code: JJX Dated: July 20, 1999 Received: July 21, 1999
Dear Mr. Hsu:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions, Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
8
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
9
510(k) Number: K991532
Device Name: DRx® Qt. hCG
INDICATIONS FOR USE
DRx® Qt. hCG is a rapid, single-use, point-of-care device for the quantitative measurement of human chorionic gonadotropin (total ßhCG) in capillary and venous whole blood samples. The device is for professional use as an aid in the assessment of pregnancy status.
Device Name: DRx® Qt. hCG Control Set
INDICATIONS FOR USE
The DRx® Qt. hCG Control Set is a two level, assayed, liquid control containing human chorionic gonadotropin for the evaluation of precision and accuracy of the DRx Ot. hCG device.
Jean Cooper
(Division Sign-off)
Division of Clinical Laboratory Devi
510(k) Number K991532
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
✓
OR
Over-The-Counter Use (Optional Format 1-2-96)